Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FIXX

Homology Medicines (FIXX) Stock Price, News & Analysis

Homology Medicines logo

About Homology Medicines Stock (NASDAQ:FIXX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.33
$16.82
52-Week Range
N/A
Volume
22,300 shs
Average Volume
390,307 shs
Market Capitalization
$978.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

FIXX Stock News Headlines

[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
FIXX Homology Medicines, Inc.
Homology Medicines Inc (FIXX)
See More Headlines

FIXX Stock Analysis - Frequently Asked Questions

Homology Medicines, Inc. (NASDAQ:FIXX) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The company had revenue of $1.68 million for the quarter, compared to analyst estimates of $0.63 million. Homology Medicines had a negative trailing twelve-month return on equity of 102.52% and a negative net margin of 4,779.31%.

Shares of Homology Medicines split on the morning of Wednesday, March 20th 2024.The 2-1 split was announced on Wednesday, March 20th 2024. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Homology Medicines (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Homology Medicines investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Enovix (ENVX), Luminar Technologies (LAZR), Advanced Micro Devices (AMD), Ginkgo Bioworks (DNA) and Tesla (TSLA).

Company Calendar

Last Earnings
11/15/2021
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FIXX
CIK
1661998
Fax
N/A
Employees
7
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($1.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$112.96 million
Net Margins
-4,779.31%
Pretax Margin
-7,532.87%
Return on Equity
-102.52%
Return on Assets
-74.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.25
Quick Ratio
7.25

Sales & Book Value

Annual Sales
$1.16 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.26 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
58,130,000
Free Float
48,774,000
Market Cap
$978.01 million
Optionable
Optionable
Beta
-0.10

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:FIXX) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners